Posts by Sandra Ansanay-Alex
Givaudan Acquires Eurofragrance
Givaudan, The Vernier-based (Canton of Geneva) global leader in Fragrance & Beauty, announced that it has reached an agreement to acquire a majority stake in Eurofragance, a pure play fragrance house based in Barcelona, Spain. The terms and conditions of the transaction have not been disclosed. Eurofragance is a family-founded fragrance creation house specialising exclusively…
Read MoreSmarter Medicine Challenge
Apply before 21 August 2026 for the Smarter Medicine Association Research Grant and get up to CHF 20,000. The association “smarter medicine – Choosing Wisely Switzerland” is committed to optimising healthcare in Switzerland. The association is inviting applications for a Research Grant. Up to three research projects may be supported, each with a maximum grant…
Read MoreNETRIS Pharma Secures €7.25 Million in EU Horizon Europe Funding
NETRIS Pharma, a clinical-stage oncology company with roots in Lyon since 2008 and a Geneva presence since 2016, has announced the award of €7.25 million under the European Union’s Horizon Europe programme. The funding will support a Phase 2b randomized clinical trial of NP137 in head and neck squamous cell carcinoma (HNSCC). NP137 targets the…
Read MoreTheraPPI closes Pre-Seed Financing Round
TheraPPI, a preclinical biotech company operating both in Lyon (France) and Geneva (Switzerland), announced the second closing of its Pre-Seed financing. The amount has not been disclosed. Current shareholders, PULSALYS, FONGIT and new investors with extensive biotech experience have participated to this financing round. TheraPPI is developing protein interaction-modifying drugs to provide patients with better treatments in…
Read MoreIsomorphic Labs Raises $2.1 Billion to Scale Its AI-Powered Drug Design Engine
Isomorphic Labs, the Google DeepMind spin-off on a mission to “solve all disease” with artificial intelligence, has secured $2.1 billion in Series B funding — one of the largest financing rounds ever seen in the AI drug discovery space. The round was led by Thrive Capital, with significant participation from Alphabet and GV, and joined…
Read MoreOculis Announced Disappointing Results For its OCS-01 Eye Drops
The Vaud-based company, which specializes in neuro-ophthalmology and ophthalmology, stated that the primary endpoint of the DIAMOND trials was not met, leading to the decision not to pursue regulatory approval with the FDA for OCS-01 in the treatment of diabetic macular edema. Despite a well-tolerated safety profile, the lack of significant improvement in visual acuity…
Read MoreTUUS gets CHF 150,000 from Venture Kick
The Vaud-based foodtech startup TUUS has obtained CHF 150,000 from Venture Kick to advance a plant-based hydrogel platform for the controlled release of nutrients and active compounds. The technology aims to provide more stable absorption and improved tolerance in applications ranging from sports nutrition to pharmaceuticals. Endurance athletes often rely on energy gels that cause…
Read MoreEPFL Latsis Symposium
The EPFL Latsis Symposium 2026: “Decoding the Cell: Modeling, Predicting, and Engineering Cellular States” is taking place on 29-30 October 2026 at the Olympic Museum in Lausanne. This two-day symposium brings together world-leading scientists at the intersection of computational biology, single-cell genomics, bioengineering, and cellular engineering – including speakers from Stanford, Cambridge, Harvard, the Wellcome Sanger Institute, and ETH Zurich, among…
Read MoreABILITY Neurotech Receives IMDD Approval to Start Clinical Trial for Chronic Implantation of BCI in ALS Patients
ABILITY Neurotech, a Geneva-based clinical-stage brain-computer interface company, announced it has received Investigational Medical Device Dossier (IMDD) approval from the Medical Research Ethics Committee (MREC) NedMec in the Netherlands to launch its first chronic implantation study of a fully implantable wireless optical-link ECoG BCI in amyotrophic lateral sclerosis (ALS) patients. This milestone represents the company’s…
Read MoreEli Lilly Makes Three Strategic Acquisitions to Bolster Its Vaccine Portfolio
Eli Lilly, the American pharmaceutical giant with a Swiss presence through its branch in Vernier, in the canton of Geneva, has announced the simultaneous acquisition of three companies — Curevo (US), LimmaTech Biologics (Switzerland), and Vaccine Company (US) — in a bold move to strengthen its position in differentiated vaccine technologies and address major unmet…
Read More